MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

Viking Therapeutics Inc

Отворен

СекторЗдравеопазване

24.8 -3.99

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.3

Максимум

25.87

Ключови измерители

By Trading Economics

Приходи

-10M

-35M

EPS

-0.32

Служители

36

EBITDA

-9.6M

-46M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+248.66% upside

Дивиденти

By Dow Jones

Следващи печалби

23.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-570M

2.7B

Предишно отваряне

28.79

Предишно затваряне

24.8

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Viking Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2025 г., 14:14 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7.02.2025 г., 10:30 ч. UTC

Топ новини

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23.12.2024 г., 15:04 ч. UTC

Топ новини

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13.12.2024 г., 14:53 ч. UTC

Топ новини

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4.11.2024 г., 12:22 ч. UTC

Топ новини

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4.11.2024 г., 12:00 ч. UTC

Топ новини

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4.11.2024 г., 10:11 ч. UTC

Горещи акции

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4.10.2024 г., 12:01 ч. UTC

Топ новини

As Weight-Loss Drugs Battle, Upstart Viking -2-

4.10.2024 г., 12:01 ч. UTC

Топ новини

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20.09.2024 г., 13:55 ч. UTC

Топ новини

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25.07.2024 г., 15:03 ч. UTC

Печалби

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Viking Therapeutics Inc Прогноза

Ценова цел

By TipRanks

248.66% нагоре

12-месечна прогноза

Среден 89.92 USD  248.66%

Висок 125 USD

Нисък 30 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Viking Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

15

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

25.48 / 25.7Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.